15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Avalo Therapeutics Inc, 10 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $30.00 to $60.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $45.10 sits 129% above the current $19.73. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near -100% this year and 0% next, consensus EPS building from about $-0.51 next quarter toward $-2.74 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Strong Buy
Strong Buy00%
Buy10100%
Hold00%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to Avalo Therapeutics Inc.
As of Sep, 10 of 10 firms rate AVTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
AVTX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.51
Range $-0.70 – $-0.39 · 7 analysts · +39% YoY
Next period, 7 analysts expect Avalo Therapeutics Inc to earn $-0.51 a share (range $-0.70 – $-0.39), versus $-0.37 a year earlier. Full-year consensus is $-2.72, growing to $-2.74 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 7 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Avalo Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AVTX.
#1
Yatin Suneja
Guggenheim · Rank #21
Buy
$48.00+143.3% to target
Overall win rate
53%
+ Follow
#2
Jason Butler
JMP Securities · Rank #31
Buy
$55.00+178.8% to target
Overall win rate
53%
+ Follow
#3
Yasmeen Rahimi
Piper Sandler · Rank #188
Buy
$60.00+204.2% to target
Overall win rate
33%
+ Follow
#4
Mitchell Kapoor
HC Wainwright & Co. · Rank #193
Buy
$30.00+52.1% to target
Overall win rate
34%
+ Follow
#5
EW
Edward White
HC Wainwright & Co. · Rank #290
Hold
No targeton AVTX
Overall win rate
31%
+ Follow
AVTX stock forecast FAQ
What is AVTX's average 12-month price target?+
The 10 analysts with a live target average $45.10 for Avalo Therapeutics Inc over the next 12 months, ranging from a $60.00 high to a $30.00 low.
Is AVTX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 10 analyst ratings, 10 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for AVTX?+
The Street-high target is $60.00 (Piper Sandler), and the Street-low is $30.00 (HC Wainwright & Co.). The average of all 10 active targets is $45.10.
How many Wall Street analysts cover AVTX?+
10 analysts have an active rating on Avalo Therapeutics Inc, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering AVTX?+
Among analysts who currently cover AVTX, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #21). Their current call is Buy with a $48.00 target.
What is Avalo Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.51 per share (range $-0.70 – $-0.39) across 7 analysts. Full-year EPS is projected at $-2.72, rising to $-2.74 the following year.
How much revenue is Avalo Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading AVTX lately?+
As of Sep, 10 of 10 firms rate AVTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AVTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
